PMID- 2140832
OWN - NLM
STAT- MEDLINE
DCOM- 19900711
LR  - 20071115
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 70
IP  - 6
DP  - 1990 Jun
TI  - Circulating forms of human atrial natriuretic peptide in patients with congestive 
      heart failure.
PG  - 1603-7
AB  - To elucidate the circulating forms of human atrial natriuretic peptide (hANP) in 
      patients with congestive heart failure (CHF), plasma samples obtained from 36 
      patients with CHF were analyzed and compared with those from normal subjects. 
      Plasma concentrations of hANP-like immunoreactivity (LI) from normal subjects and 
      patients with mild CHF (class I), as classified by the New York Heart Association 
      (NYHA) functional criteria, did not differ (15 +/- 1 vs. 16 +/- 1 pmol/L, mean 
      +/- SE), whereas plasma levels of hANP-LI in patients with moderate and severe 
      CHF significantly (P less than 0.01) increased in relation to the severity of CHF 
      (class II, 44 +/- 4 pmol/L; class III, 116 +/- 24 pmol/L; class IV, 141 +/- 21 
      pmol/L). Reverse-phase HPLC and gel permeation chromatography coupled with RIA 
      for hANP revealed that the circulating forms of hANP-LI consisted of alpha-hANP, 
      beta-hANP, and gamma-hANP in CHF, whereas alpha-hANP predominated in normal 
      plasma. The percentage of beta-hANP in total hANP-LI as calculated from the 
      chromatograms by gel filtration was greater in severe CHF (NYHA class III and IV) 
      than those in mild CHF (NYHA class I and II), and apparently exceeded those of 
      other forms. Successful medical treatment for CHF resulted in a marked reduction 
      of total plasma hANP-LI levels with a concomitant disappearance or reduction of 
      beta-hANP in 14 patients examined. These data suggest that beta-hANP and 
      gamma-hANP are secreted from the failing human heart, possibly resulting from the 
      augmented synthesis and/or the altered processing of hANP precursor in 
      cardiocytes, and that circulating beta-hANP may serve as a potential marker for 
      the severity of CHF in man.
FAU - Ando, K
AU  - Ando K
AD  - Second Department of Internal Medicine, Tokyo Medical and Dental University, 
      Japan.
FAU - Hirata, Y
AU  - Hirata Y
FAU - Emori, T
AU  - Emori T
FAU - Shichiri, M
AU  - Shichiri M
FAU - Kurosawa, T
AU  - Kurosawa T
FAU - Sato, K
AU  - Sato K
FAU - Marumo, F
AU  - Marumo F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Natriuretic Factor/analysis/*blood
MH  - Chromatography, Gel
MH  - Chromatography, High Pressure Liquid
MH  - Female
MH  - Heart Failure/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Radioimmunoassay
EDAT- 1990/06/01 00:00
MHDA- 1990/06/01 00:01
CRDT- 1990/06/01 00:00
PHST- 1990/06/01 00:00 [pubmed]
PHST- 1990/06/01 00:01 [medline]
PHST- 1990/06/01 00:00 [entrez]
AID - 10.1210/jcem-70-6-1603 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 1990 Jun;70(6):1603-7. doi: 10.1210/jcem-70-6-1603.